Nimotop (Nimodipine)

Nimodipine selectively blocks L‑type voltage‑gated calcium channels on the smooth muscle of cerebral arteries. This reduces calcium entry into the cells, causing relaxation of the vessel wall and preferential dilation of intracranial arteries, which improves cerebral perfusion without causing major systemic blood‑pressure changes.

The dosage and infusion rate of Nimotop are determined by the treating physician based on the patient’s clinical condition, weight, and response. Prescribers follow local guidelines and product labeling to set the appropriate regimen; specific dosing information is not provided here.

Nimotop is classified as a prescription‑only medication and should be used in pregnancy or lactation only when the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate each case individually and discuss possible effects with the patient.

To request Nimotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimotop (nimodipine) is distinguished by its high lipophilicity, which enables selective penetration of the blood‑brain barrier and preferential dilation of cerebral vessels. Other vasodilators may act systemically and cause more pronounced hypotension, whereas nimodipine’s effect is largely confined to intracranial arteries, making it the preferred choice for subarachnoid‑hemorrhage‑related vasospasm.

Nimotop should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. The container should remain sealed until use, and any unused portion should be discarded according to local regulations after the labeled expiration date.

Nimotop is supplied as an intravenous solution and is administered by slow infusion under the supervision of qualified healthcare personnel. The infusion rate is adjusted according to the patient’s hemodynamic status, and continuous monitoring of blood pressure and cardiac function is recommended throughout the administration period.

The most serious adverse events associated with Nimotop include severe hypotension, myocardial infarction, life‑threatening arrhythmias, and rare allergic reactions such as anaphylaxis. Prompt recognition of these signs and immediate medical intervention are essential to mitigate potential harm.

Nimotop is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation, and in individuals with severe uncontrolled hypotension. Caution is also advised for patients with significant cardiac disease, hepatic impairment, or those taking interacting medications that could exacerbate hypotensive effects.